Profile
NewVale Capital is a growth equity firm based in Boulder, Colorado, founded in 2022. The firm is led by a team of experienced professionals including Managing Partner Todd Holmes and Operating Partners Scott Waldman and Anne Whitaker. NewVale Capital focuses on the life sciences sector, particularly in services and enabling technologies that support drug discovery, clinical research, manufacturing, and commercialization.
The firm invests in revenue-generating businesses within the life sciences ecosystem, with a typical investment size in the Series B and Series C stages. NewVale Capital's geographic focus is primarily on the United States, and it manages assets through its NewVale Capital Fund I, which launched in 2024 with $167 million in assets under management.
Notable investments by NewVale Capital include Aizon - an AI-enabled software platform for pharmaceutical manufacturing, Argonaut - a CDMO specializing in aseptic drug product fill/finish, Beaconcure - a clinical data validation platform, CAI - a global engineering and technical services firm, and Noxilizer - a company providing nitrogen dioxide-based sterilization technology.
Industry
NewVale Capital Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
NewVale Capital Fund I
|
Private Equity (PE)
|
Healthcare Services
|
Series B
Late Stage (Series C+)
|
North America
|
$5-10 m
|
$167 M
|
May 2024
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.